The World Health Organization (WHO) was first notified of a cluster of unexplained pneumonia cases in Wuhan, China, on December 31, 2019. Over the first six months of 2020, coronavirus disease 2019 (COVID-19) became a global pandemic with over 10 million confirmed cases and over 500,000 deaths by the end of June.([@bib1]) Although the causative agent of COVID-19 -- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) -- has proven difficult to contain, infection in children and adolescents has generally resulted in more mild or asymptomatic cases compared with adults.([@bib2], [@bib3], [@bib4])

On April 25, 2020, the United Kingdom's National Health Service (UK NHS) alerted physicians of a newly recognized syndrome with severe multisystem inflammation in children with clinical features similar to those found in Kawasaki disease and toxic shock syndrome (TSS).([@bib5]) The new syndrome was temporally associated with COVID-19, with the development of symptoms typically about 3-4 weeks after escalation of geographically local COVID-19 incidence. Subsequent reports from other European countries and the United States (US) identified additional cases of children exhibiting a hyperinflammatory syndrome with multisystem involvement; many of the patients had laboratory confirmation of current or previous SARS-CoV-2 infection through reverse transcriptase-polymerase chain reaction (RT-PCR) or serological tests.([@bib6]) The first published study of MIS-C-patients described eight children from the UK with hyperinflammatory shock;([@bib7]) since then, several additional descriptive studies have contributed a wider breadth of knowledge about the clinical picture for the syndrome, now referred to as multisystem inflammatory syndrome in children (MIS-C).([@bib8], [@bib9], [@bib10])

Health officials have adjusted the clinical and epidemiologic criteria used to identify cases as the understanding of MIS-C has evolved. MIS-C is a novel syndrome for which no confirmatory diagnostic test exists. Clinical practice, including diagnostic criteria, for MIS-C have varied across time and setting. Therefore, studies of MIS-C may substantially differ in case inclusion criteria, laboratory values tested, and treatments administered. The purpose of this systematic review is to compare and summarize currently published studies to provide an overview of the clinical picture of MIS-C that accounts for these different settings and case inclusion criteria from different settings.

Methods {#sec1}
=======

Literature searches were conducted using PubMed and Embase for papers published from April 25, 2020 through June 29, 2020. Given the novelty of MIS-C, preprint manuscripts uploaded to medRxiv and bioRxiv servers during the same timeframe were also searched. Due to the rapidly evolving understanding of MIS-C, a variety of search terms were utilized to identify reports of MIS-C cases. The search terms included the following phrases or combinations of phrases "multisystem inflammatory syndrome"; "kawasaki disease"; "hyperinflammatory"; "hyperinflammation"; "toxic shock syndrome"; "shock" with "children" or "pediatric"; "cytokine" with "children" or "pediatric"; "inflammation" or "inflammatory" with "syndrome" and "children" or "pediatric."

Studies on MIS-C cases have used different names for the syndrome and used different criteria to identify cases. To ensure that no studies were missed through keyword searches, Google Scholar was used to search through any studies that cited two early, impactful publications on MIS-C.([@bib7], [@bib10])

Papers identified through all searches were examined to determine if they were studies describing patients with clinical and epidemiologic characteristics consistent with MIS-C as defined by the UK Royal College of Paediatrics and Child Health (RCPCH), New York State Department of Health, the US Centers for Disease Control and Prevention (CDC),([@bib11]) or the WHO.([@bib12]) Studies describing patients fitting the following criteria were included in the analysis:1) young age (typically under 21 years old); 2) severe cardiovascular or multisystem clinical manifestations; 3) laboratory evidence of inflammation; 4) either laboratory evidence of SARS-CoV-2 infection or epidemiological association with COVID-19 (including temporal association with periods of high local COVID-19 transmission). Additionally, given the substantial clinical overlap between MIS-C and KD, another syndrome without a diagnostic test, studies describing KD patients with laboratory or epidemiologic links to SARS-CoV-2 were included in this systematic review.

Only studies that described at least 5 MIS-C cases were included, and studies with MIS-C patients largely or entirely described in other publications were excluded. We used information on setting (dates of case identification and healthcare setting) to identify potential duplication of patients between studies, following up with study authors for additional information. Data collected from the papers included: case inclusion criteria, demographic information, clinical signs/symptoms and outcomes, laboratory markers of inflammation and cardiovascular function, and treatments administered. Studies that did not sufficiently describe the above data were excluded. Median and interquartile range (IQR) for laboratory values were captured if reported by each study, along with the proportion of patients with abnormal values using reference ranges reported for each study. For studies that reported median and IQR but not the proportion with abnormal values, the range of possible proportions was reported based on which percentile values fell outside reference ranges (For example, if the reported 25^th^ percentile was within the reference range but the median was above it, we know that between 50-75% of patients in the study had elevated values for that marker).

Studies were divided into three categories based on inclusion criteria; studies with cardiovascular involvement as a requirement for inclusion; patients meeting KD clinical case definition(13) as a requirement for inclusion; and broader criteria that captured patients with multisystem involvement along with evidence of inflammation and links to COVID-19. Generalized linear mixed models with double arcsine-transformed proportions(14) were used to assess differences in prevalence of clinical symptoms and treatments administered by study category. The mixed model approach allowed for the comparison of proportions by inclusion criteria while accounting for study heterogeneity.([@bib15])

Statistical analyses were performed using R version 4.0.2 (The R Foundation for Statistical Computing, 2020).

Results {#sec2}
=======

A total of 1,470 records (440 from PubMed, 734 from Embase, 65 from medRxiv and bioRxiv, and record 231 from subsequent citations) were reviewed for possible inclusion (Figure 3; available at [www.jpeds.com](http://www.jpeds.com){#intref0010}). After review, 20 studies were identified that described cohorts of at least five MIS-C cases.([@bib7], [@bib8], [@bib10], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32]) Ten of the studies(7, 17-20, 23-26, 30) were excluded due to likely substantial overlap of patients with other studies; this included the report of MIS-C patients from Riphagen et al whose patients were all included in a subsequent larger study. ([@bib7])(32) An additional two studies (describing n=116 patients) were excluded due to insufficient data on clinical features and laboratory markers.([@bib16], [@bib27]) A study from Toubiana et al.([@bib31]) was not excluded despite possibly having patients in common with a larger multi-institutional study,([@bib8]) as due to the brief period of overlap (the study time periods were 15 days and 40 days, and the overlap was only 4 days) as well as different inclusion criteria, the number of patients in common was likely minimal (the authors could not be reached for comment).

Eight published studies were included in this systematic review that captured a total of 440 patients.([@bib8], [@bib10], [@bib21], [@bib22], [@bib28], [@bib29], [@bib31], [@bib32]) ([Table I](#tbl1){ref-type="table"} ). The total number of patients included in the studies ranged from 10 to 186. The two largest studies were from the US, and the other six studies were from European countries. Primary inclusion criteria for three of the European studies (one from Italy and two from France) was a diagnosis of KD.([@bib10], [@bib28], [@bib31]) Two studies required cardiovascular system involvement: one study from the UK(29) selected children referred for cardiovascular evaluation and who met the UK RCPCH criteria for MIS-C;([@bib33]) another study in France and Switzerland identified children with acute left ventricular systolic dysfunction or cardiogenic shock along with an associated multisystem inflammatory state.([@bib8]) Two studies from the US(21, 22) and one from the UK(32) used broader inclusion criteria which included fever, multisystem involvement, and laboratory evidence of inflammation; the US studies also required laboratory or epidemiologic link to COVID-19. Full inclusion criteria for each study are detailed in the Appendix \[available at [www.jpeds.com](http://www.jpeds.com){#intref0015}.Table 1Overview of studies included in the systematic reviewWhittaker (JAMA)^32^Verdoni (Lancet)^10^Belhadjer (Circulation)^8^Toubiana (BMJ)^31^Dufort (NEJM)^21^Feldstein (NEJM)^22^Ramcharan (Pediatric Cardiology)^29^Pouletty (Pediatric Rheumatology)^28^LocationUnited Kingdom (8 hospitals)Bergamo, Italy (Papa Giovanni XXIII Hospital)12 hospitals in France and 1 in SwitzerlandParis, France (Necker-Enfants-Malades Hospital)New York state, US53 sites in 27 US statesBirmingham, England (Birmingham Children\'s Hospital)5 hospitals in the Paris areaN58103521991861516Case hospitalization date rangeMarch 23 - May 16February 18 - April 20March 22 - April 30April 27 - May 11March 1 - May 10March 15 - May 20April 10 - May 9April 7 - April 30Other inclusion criteriaChildren meeting UK, WHO, or CDC criteria (without requiring proof of SARS-CoV exposure)Patients diagnosed with Kawasaki disease (complete or incomplete)Children with acute left ventricular systolic dysfunction or cardiogenic shock and associated multisystem inflammatory stateChildren ≤18 years who met criteria for Kawasaki disease (complete or incomplete)New York state case definition: clinical and lab and/or epi criteria (includes positive SARS-COV-2 test or reported exposure)^51^Clinical and lab and/or epi criteria (includes positive SARS-COV-2 test or reported exposure)All patients referred for cardiovascular evaluation as confirmed\
PIMS-TS\<18 years, complete or incomplete KD,\
SARS-CoV-2 PCR+ or serology+ and/or close contactMedian age, years (IQR)9 (5.7 - 14)7.3 (5.4 - 8.5)10 (IQR NA)7.9 (3.7 - 16.6)NA8.3 (3.3 - 12.5)8.8 (6.4 - 11.2)10 (4.7 - 12.5)Sex (percent male)66%70%51%43%54%62%73%50%Race/ethnicity38% Black\
31% Asian\
21% White\
10% OtherNANA57% Afro-Caribbean\
29% European\
10% Asian\
5% Middle Eastern40% Black\
37% White\
5% Asian\
18% Other;\
36% Hispanic^1^39% Hispanic\
31% Black non-Hispanic\
24% White non-Hispanic\
6% Other^2^40% Afro-Caribbean\
40% South Asian\
13% Mixed\
7% Other62% Afro-Caribbean\
25% European 12% Middle EasternSARS-CoV-2 PCR (%)26%26%20%34%51%40%13%69%SARS-CoV-2 Serology (%)87%83%80%86%99%75%100%100%Length of hospital stay: median days (IQR)NANA886 ([@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9])7 ([@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10])12 ([@bib9], [@bib10], [@bib11], [@bib12], [@bib13])NADied2%0%0%0%2%2%0%0%[^1][^2][^3]

Median age of patients by study ranged from 7.3 to 10 years, and 59% of all patients (43%--73% across studies) were male. In the six studies that reported race/ethnicity data, the proportion of black or Afro-Caribbean patients ranged from 31 to 62%. The two US studies reported Hispanic ethnicity, which comprised 36-39% of patients. Across all studies, the proportion of patients with positive SARS-CoV-2 RT-PCR test results ranged from 13 to 69%, and the proportion with positive serology tests ranged from 75 to 100%. Seven (2%) of the 440 MIS-C patients died.

[Figure 1](#fig1){ref-type="fig"} shows the proportion of patients in each study with clinical manifestation by different organ systems. Overall, the highest proportion of patients had gastrointestinal symptoms (87%) followed by dermatologic/mucocutaneous symptoms (73%) and cardiovascular symptoms (71%), with fewer patients reporting respiratory (47%), neurologic (22%), and musculoskeletal (21%) symptoms. The proportion reporting cardiovascular symptoms, neurologic symptoms, and respiratory symptoms differed by inclusion criteria. The studies which used cardiovascular inclusion criteria had a prevalence of cardiovascular symptoms of 100%, and studies selecting KD patients included higher prevalence of neurologic symptoms (55%) but lower prevalence of respiratory symptoms (14%).Figure 1Proportion of patients with clinical symptoms in different organ systems by study. Size of circles is relative to study sample size, and colors represent categories of inclusion criteria. Grey bars represent the prevalence of organ system involvement in patients in all studies. Not all studies reported involvement for each organ system. Point labels denote studies: W=Whittaker, V=Verdoni, B=Belhadjer, T=Toubiana, D=Dufort, F=Feldstein, R=Ramcharan, P=Pouletty. Studies with inclusion criteria of cardiovascular disorder (CVD) and Kawasaki disease (KD) were assessed for differences in proportions compared with studies with broader inclusion criteria: \[ns\]=not significant, \*= *P* \< .05, \*\*=p\<0.01, \*\*\*=p\<0.001.

[Figure 2](#fig2){ref-type="fig"} shows the proportion of patients in each study receiving different therapies. Of listed therapies, intravenous immunoglobulin (IVIG) was the most commonly administered (76% of patients) compared with vasoactive medications (53%), steroids (52%), and immune modulators (18%). In addition, 26% of patients received intubation, and 6% required extracorporeal membrane oxygenation (ECMO). IVIG was given to 98% of patients from the studies selecting KD patients. Studies using cardiovascular inclusion criteria had lower prevalence of treatment with steroids (34%) but higher prevalence of use of ECMO (20%).Figure 2Proportion of patients receiving different types of treatment by study. Size of circles is relative to study sample size, and colors represent categories of inclusion criteria. Grey bars represent the proportion of patients receiving treatments in all studies. Not all studies reported each type of treatment. Point labels denote studies: W=Whittaker, V=Verdoni, B=Belhadjer, T=Toubiana, D=Dufort, F=Feldstein, R=Ramcharan, P=Pouletty. Studies with inclusion criteria of cardiovascular disorder (CVD) and Kawasaki disease (KD) were assessed for differences in proportions compared with studies with broader inclusion criteria: \[ns\]=not significant, \*=p\<0.05, \*\*=p\<0.01, \*\*\*=p\<0.001.Figure 3Flowchart of literature search and study identification

[Table 2](#tbl2){ref-type="table"} summarizes laboratory test results reported by each study. In every study for which the proportion of patients with abnormal levels could be ascertained, ferritin and d-dimer levels were elevated in at least 50% of patients, and C-reactive protein, interleukin-6, and fibrinogen were elevated in each study in at least 75% of patients. Decreased platelet levels were also commonly observed in many studies. Highly elevated levels for markers of cardiac damage -- troponin, brain natriuretic peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP) -- were seen in the majority of patients across studies and were observed in potentially 100% of patients for the studies with cardiovascular inclusion criteria.Table 2Laboratory test results by study. Threshold for abnormal values is determined by study. Results highlighted in yellow describe abnormal values in at least 50% of patients; results highlighted in green describe abnormal values in fewer than 50% of patients; results not highlighted have insufficient data to estimate the proportion of patients with abnormal values. Results with ranges for % abnormal signify that these percentages were estimated by comparing the interquartile range (IQR) with the reference range.Whittaker (JAMA)Verdoni (Lancet)Belhadjer (Circulation)Toubiana (BMJ)Dufort (NEJM)Feldstein (NEJM)Ramcharan (Pediatric Cardiology)Pouletty (Paediatric Rheumatology)WBC (\*1000/μL)median17-1617.410.4\--11.5IQR([@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22])-([@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23])(5.4-42.8)^1^(6.7-14.5)\--(9-14.4)% abnormal50-75% (\>13.5)-∼75% (\>12)\-\--Neutrophils (\*1000/μL)median1384^7^1313.682^7^\--9.2IQR([@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19])(79-90)^7^([@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19])(3.3-36.4)^1^(76.0-89.0)^7^\--(7.6-10.7)% abnormal75-100% (\>7)70% (\>80)^7^50-75% (\>8.5)\--68% (\>7.7)Lymphocytes (\*1000/μL)median0.80.8-1.110^7^\--1.15IQR(0.5-1.5)(0.5-1.0)-(0.4-5.6)^1^(5.0-16.0)^7^\--(0.8-1.7)% abnormal∼75% (\<1.5)90% (\<1.5)81%^4^66%^2^80%^3^Platelets (\*1000/μL)median151130\--155133-188IQR(104-210)(118-144)\--(105-233)(88-235)-(164-244)% abnormal50-75% (\<200)100% (≤300)11% (\<80)55% (\<150)ESR (mm/hr)median-71\--61.56575-IQR-(52-94)\--(43.0-77.5)(42-91)(45-90)-% abnormal77% (\>40)77% (\>40)75-100% (\>9)Ferritin (ng/mL)median610893\--5226395581067IQR(359-1280)(324-2000)\--(305-820)(333-1178)(364-1325)(272-1709)% abnormal75-100% (\>140)56% (\>684)\--75% (\>300)61% (\>500)75-100% (\>79)50% (\>500)CRP (mg/L)median229241241253219178154207IQR(156-338)(110-353)(150-311)(89-363)^1^(150-300)(128-259)(129-231)(162-236)% abnormal75-100% (\>5)80% (\>100)100% (\>6)-87% (\>100)91% (\>30)75-100% (\>10)100%^4^Albumin (g/L)median24\--213125-21IQR([@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27])\--([@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37])^1^([@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36])([@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29])-([@bib19], [@bib20], [@bib21], [@bib22], [@bib23])% abnormal75-100% (\<35)\--95% (\<32)48% (\<30)80% (\<30)43%^4^IL-6 (pg/mL)median\--135170116.3\-\--IQR\--(87-175)(4-1366)^1^(37.0-315.0)\-\--% abnormal-75-100% (\>8.5)-97% (\>5)-Troponin (ng/L)median45111347282\--39658IQR(8-294)(18-1879)(186-1267)(10-6900)^1^\--(100-1280)(36-165)% abnormal68% (\>15)56% (\>53)75-100% (\>26)81% (\>26)71%^4^50%^5^100% (\>35)Fibrinogen (mg/dL)median570618-499624\-\--IQR(440-700)(483-759)-(78-838)^1^(506-764)\-\--% abnormal75-100% (\>409)90% (\>360)86% (\>400)80% (\>400)D-dimers (ng/mL)median3578-52844025240040902060-IQR(2085-8235)-(4069-9095)(350-19330)^1^(1200-3700)(2240-8405)(1160-2610)-% abnormal75-100% (\>560)-100% (\>500)95% (\>500)91% (\>550)67% (\>3000)75-100% (\>300)BNP (pg/mL)median\--57433354-1195\--IQR\--(2648-11909)(16-16017)^1^-(391-4833)\--% abnormal100% (\>100)\--73% (\>400)proBNP (ng/L)median788123641484\-\--24470-IQR(174-10548)(295-1921)(35811-52475)\-\--(17212-26655)-% abnormal83% (\>100)100% (\>100)100% (\>100)-90%^6^-100% (\>400)[^4][^5][^6][^7][^8][^9][^10]

Discussion {#sec3}
==========

Our review summarizes and compares data from eight separate studies that describe patients with MIS-C identified in various settings using different inclusion criteria. MIS-C patients predominantly had fever with gastrointestinal, cardiovascular, and mucocutaneous manifestations which was consistent across studies despite the different inclusion criteria. Respiratory manifestations, which are predominant manifestations in COVID-19, were described in a minority of MIS-C patients. All studies reported highly elevated levels of C-reactive protein and other laboratory markers of inflammation suggesting that hyperinflammatory state is a primary hallmark of MIS-C. The studies represent an evolving understanding of the clinical manifestations and management of this novel condition. Because the UK NHS's initial alert described cases similar to atypical KD or toxic shock syndrome, the early published studies focused their analyses either on patients diagnosed with KD or patients with shock and other cardiovascular disorders.([@bib7], [@bib8], [@bib10], [@bib31]) Many of the more recently published studies allowed for the inclusion of patients with more encompassing multisystem involvement along with laboratory evidence of inflammation.([@bib21], [@bib22], [@bib32])

The studies describing patients diagnosed as KD or with required cardiovascular inclusion criteria most likely represent subsets of MIS-C as defined by the broader case definitions used by the UK, New York State, CDC, and WHO. The patients described by Riphagen et al all had multisystem involvement, laboratory evidence of inflammation, and positive serological tests for SARS-CoV-2, and they all would have met the above case definitions.([@bib7]) Similarly, the patients in other studies(8, 10, 28, 29, 31) also overwhelmingly had multisystem involvement, laboratory evidence of inflammation, and positive tests for SARS-CoV-2. Conversely, substantial proportions of patients in the studies with broader case definitions would have met inclusion criteria for the other studies: many patients in other cohorts(21, 22, 32) received diagnoses of KD (22%, 36%, and 40%, respectively) or had evidence of shock (50%, 10%, and 48%, respectively).

Importantly, although many MIS-C cases share clinical features similar to KD, increasing evidence suggests that they are two separate syndromes. Although MIS-C and KD present with some phenotypic similarities, there are several epidemiological and clinical features distinguishing the two diseases. Approximately 80% of KD cases are under 5 years old with a median age of 2 years(34, 35) and the median age for patients reported in all eight MIS-C studies was at least 7 years. KD incidence is dramatically higher among Japanese children and other children of East Asian descent. In contrast, the MIS-C studies do not describe a preponderance among children of East Asian descent, and despite extensive spread of COVID-19 in some East Asian countries, reports of MIS-C in that region are largely absent.([@bib35]) Verdoni et al reported that patients meeting KD diagnostic criteria associated with COVID-19 had lower white blood cell count and lower platelet levels but higher levels of C-reactive protein and ferritin compared with cases of KD from before the COVID-19 pandemic.([@bib10]) Whittaker et al reported that MIS-C cases had higher levels of neutrophils, C-reactive protein, ferritin, troponin, and d-dimers compared with a historic KD cohort, but lower levels of lymphocytes and platelets.([@bib32]) MIS-C cases exhibit higher prevalence of multisystem involvement, notably cardiac abnormalities such as myocarditis and shock.([@bib35]) KD is a clinically diagnosed syndrome, thus given overlap in clinical features with MIS-C, a substantial proportion of MIS-C cases may continue to be classified as KD as more children are exposed to SARS-CoV-2. Early reports support the use of IVIG, which is the standard treatment for KD, for use in treating MIS-C patients;([@bib7], [@bib9], [@bib23]) corticosteroids also have an important role in KD treatment and the same may prove true for MIS-C.([@bib19]) Despite this, there may be key etiological and pathophysiologic differences between KD and MIS-C, and distinguishing the two syndromes may be important for establishing best practices for MIS-C treatment and prevention.

In all studies, the proportion of patients with positive SARS-CoV-2 serology testing was substantially higher than of those with positive SARS-CoV-2 RT-PCR tests. These findings as well as increased markers of hyperinflammation are consistent with the hypothesis that MIS-C results from a post-infectious inflammatory process.([@bib21], [@bib35], [@bib36]) Multiple reports(21, 22, 37) describe a 4-6 week delay between the proliferation of local COVID-19 cases and the surge in MIS-C cases, whereas Feldstein et al describe a median of 22 days between onset of COVID-19 symptoms and MIS-C hospitalization.([@bib22]) In the study with the highest prevalence of RT-PCR positivity ( 69%)([@bib28]), the authors noted that the viral load reported by cycle threshold was low in almost all patients and that all patients with serological assessments were IgG positive, suggesting a substantial delay between the timing of SARS-CoV-2 infection and onset of MIS-C symptoms and subsequent RT-PCR testing. One interesting note is that the two large studies with the broader inclusion criteria (([@bib21], [@bib22]) had relatively large proportions of patients who tested positive by PCR (51% and 40%, respectively); they also had higher proportions of patients with respiratory symptoms (40% and 70%, respectively). The inclusion criteria for these studies may have captured a greater number of cases with severe acute COVID-19, and the etiology of those cases may be different from that of post-infectious MIS-C cases.

Fifty-nine percent of MIS-C patients across all studies were male. All but one study reported at least 50% of patients as males. In contrast, boys represent just under 50% of all laboratory-confirmed COVID-19 cases under 20 years in both the US and the UK.([@bib38], [@bib39]) This suggests that males infected with SARS-CoV-2 may be more likely to develop MIS-C, similar to KD in which studies have reported a male to female ratio of ∼1.5 to 1 across many countries.([@bib40])

Certain racial and ethnic groups may also be disproportionately affected by MIS-C. The proportions of Hispanic patients in the Dufort et al and Feldstein et al studies (36% and 39%) are higher than the proportions of all Hispanic residents in New York state and in the entire US (19.3% and 18.5% respectively). ([@bib21], [@bib22]) ([@bib41]) However, the proportion of MIS-C patients of Hispanic origin may not differ substantially from the proportion Hispanic reported in SARS-CoV-2 seroprevalence surveys among adults in several areas of New York State (36.6%)([@bib42]) and the proportion of US COVID-19 cases that are Hispanic (33.4%).([@bib41], [@bib43]) Conversely, the proportions of MIS-C patients reported as black or Afro-Caribbean may be higher than proportions in both the underlying populations and in reported COVID-19 cases. The proportion of black patients in the Feldstein et al study (31%) is higher than the proportions of black residents in the US (13.4%) and the proportion of all US COVID-19 patients who are black (16%).([@bib22]) ([@bib41]) ([@bib43], [@bib44]) Similarly, the proportion of black patients in the Dufort et al study (40%) is higher than the proportions of black residents in New York State (17.6%) and in SARS-CoV-2 seroprevalence surveys among adults in several areas in New York State (20.2%).([@bib21]) ([@bib41])(42) The proportion of MIS-C patients who are black (38% and 40%) or Asian (31% and 40%) in the two studies from the UK(29, 32) (specifically, England) are higher than the proportions of Black or Asian residents in England (3.5% and 8.0%, respectively)([@bib45]) and Black and Asian proportions of all English COVID-19 cases (4.6% and 9.6%, respectively). Although the exact cause of these disparities may be unknown, conditions in the places where people live, learn, work, and play affect a wide range of health risks and outcomes.([@bib46]) The link between social determinants of health, including social, economic, and environmental conditions, and health outcomes is widely recognized in the public health literature. Moreover, it is increasingly recognized that inequitable distribution of these conditions across various populations is a significant contributor to persistent and pervasive health disparities.([@bib47]) Factors affecting disadvantaged groups such as living in more crowded conditions, employment in occupations not suitable to physical distancing, higher prevalence of underlying medical conditions, and reduced healthcare access have been implicated in the greater incidence and severity of COVID-19 observed in racial/ethnic minorities.([@bib48], [@bib49]) Addressing social determinants of health that disproportionately affect certain racial/ethnic groups, while improving access to health care, is crucial to reducing the additional burden of MIS-C.

This study has several important limitations. Data for some variables of interest were either not reported for all studies or not reported in a consistent fashion, making direct comparisons between studies difficult. Potential issues included: different criteria available to assess organ system involvement, lack of information on imaging studies, timing of laboratory tests, and different thresholds for defining abnormal laboratory values. Overall proportions for variables of interest were calculated by excluding studies which did not report those variables. It is possible that those variables were excluded from these studies due to their involvement being less prominent. Additionally, the lack of a diagnostic test or universally used case inclusion criteria could have led to missed diagnosis or nonreporting of some MIS-C cases, particularly patients without a positive SARS-CoV-2 test and patients with less severe symptoms. Exclusion of those patients may lead to an incomplete picture of the overall spectrum of disease, and further investigations would help to expand upon this preliminary characterization of MIS-C. Finally, although most patients improved with treatment or by supportive care alone,([@bib32]) these descriptive studies are not sufficient for assessing the efficacy of different treatments. Efforts to better investigate treatments are currently under way,([@bib50]) and ultimately clinical trials will be necessary to determine optimal clinical management of MIS-C patients.

Data from the systematic review indicate that MIS-C cases from different studies across different countries have similar manifestations with a strong temporal, geographic, and laboratory link with SARS-CoV-2 infection. Clinical, laboratory and epidemiologic characteristics of MIS-C appear to be different from those of KD. Future studies will hopefully shed additional light on MIS-C and improve prospects for prevention and treatment of this severe pediatric condition.

Supplementary data {#appsec1}
==================

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors declare no conflicts of interest.

**Data statement:** All data in this systematic review is available from the included published studies. Requests for clarification can be made to the corresponding author at jabrams\@cdc.gov.

[^1]: Abbreviations: NA, not available; PIMS-TS, pediatric multisystem inflammatory syndrome; AI/AN, American Indian or Alaskan Native

[^2]: 1 -- Hispanic ethnicity listed separately from race

[^3]: 2 -- Among patients with known race/ethnicity

[^4]: 1 - values shown are range; IQR was not reported in the publication

[^5]: 2 - classified as lymphocytes (%): (\<2.5) under 1 month, (\<4.0) 1-12 months, (\<3) 1-2 years, (\<2) 2-4 years, (\<1.5) 4-10 years, (\<1.2) 10-16 years, (\<1.0) 16-21 years

[^6]: 3 - lymphocyte count \<1500/μL in those \>8 months old and \<4500/μL in children under eight months of age

[^7]: 4 - threshold not specified

[^8]: 5 - troponin categorized dichotomously as high or normal based on each laboratory's reference range

[^9]: 6 - elevated proBNP classified as (ng/L): (\>1,121) 1 month - 1 year, (\>675) 1-2 years, (\>391) 6-14 years, (\>363) 14-21 years

[^10]: 7 -- values given in percent white blood cells
